微小残留病阴性应作为骨髓瘤治疗的终点吗？
Should minimal residual disease negativity be the end point of myeloma therapy?
作者信息
Sonneveld Pieter
机构信息
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
出版信息
Blood Adv. 2017 Mar 14;1(8):522-525. doi: 10.1182/bloodadvances.2017000109.
Abstract
This article has a companion Point by Anderson. Join in the discussion of these articles at Community Conversations.
摘要
本文有一篇由安德森撰写的配套观点文章。请在“社区对话”中参与对这些文章的讨论。
相似文献
1
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应作为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):522-525. doi: 10.1182/bloodadvances.2017000109.
2
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应成为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):517-521. doi: 10.1182/bloodadvances.2016000117.
3
Platelets as immune-sensing cells.血小板作为免疫感知细胞。
Blood Adv. 2016 Nov 22;1(1):10-14. doi: 10.1182/bloodadvances.2016000067. eCollection 2016 Nov 29.
4
Related haploidentical donors are a better choice than matched unrelated donors: Point.相关的单倍体相合供体比匹配的无关供体是更好的选择：观点。
Blood Adv. 2017 Feb 14;1(6):397-400. doi: 10.1182/bloodadvances.2016002196.
5
Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.基于血容量的血管性血友病因子用于预防血管性血友病患者产后出血
Blood Adv. 2017 Apr 25;1(11):703-706. doi: 10.1182/bloodadvances.2017005090.
6
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？反对观点。
Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552.
7
Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.相关单倍型相合供体比匹配的无关供体是更好的选择：反对观点。
Blood Adv. 2017 Feb 14;1(6):401-406. doi: 10.1182/bloodadvances.2016002188.
8
Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.预防血管性血友病（VWD）相关产后出血的抗纤溶治疗：适应证与局限性
Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082.
9
Immunotherapy for acute lymphoblastic leukemia: from famine to feast.急性淋巴细胞白血病的免疫疗法：从匮乏到富足。
Blood Adv. 2016 Dec 27;1(3):265-269. doi: 10.1182/bloodadvances.2016000034.
10
ATG in allogeneic stem cell transplantation: standard of care in 2017? Point.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？观点。
Blood Adv. 2017 Mar 28;1(9):569-572. doi: 10.1182/bloodadvances.2016001560.
引用本文的文献
1
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.微小残留病阴性和来那度胺维持治疗与多发性骨髓瘤的更好生存结果相关。
Bone Marrow Transplant. 2020 Jun;55(6):1137-1146. doi: 10.1038/s41409-020-0791-y. Epub 2020 Jan 28.
2
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.多发性骨髓瘤骨髓中的微小残留病评估：对注意事项、临床意义及未来展望的综述
Front Oncol. 2019 Aug 20;9:699. doi: 10.3389/fonc.2019.00699. eCollection 2019.
3
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.达雷妥尤单抗：复发和/或难治性多发性骨髓瘤的治疗药物。
Drugs. 2017 Dec;77(18):2013-2024. doi: 10.1007/s40265-017-0837-7.
本文引用的文献
1
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
2
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.微小残留病与多发性骨髓瘤患者更好的生存结果的关联：一项荟萃分析。
JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.
3
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
4
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
5
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.来那度胺、伊沙佐米和地塞米松联合治疗多发性骨髓瘤。
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
6
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.Daratumumab 单药治疗多发性骨髓瘤中针对 CD38。
N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.
7
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.PET/CT 改善完全缓解定义，并可发现多发性骨髓瘤中其他无法识别的骨骼进展。
Clin Cancer Res. 2015 Oct 1;21(19):4384-90. doi: 10.1158/1078-0432.CCR-15-0396. Epub 2015 Jun 15.
8
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.依鲁替尼联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项多中心、开放标签的 II 期研究
N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.
9
New criteria for response assessment: role of minimal residual disease in multiple myeloma.反应评估的新标准：微小残留病在多发性骨髓瘤中的作用。
Blood. 2015 May 14;125(20):3059-68. doi: 10.1182/blood-2014-11-568907. Epub 2015 Apr 2.
10
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.卡非佐米、来那度胺和地塞米松治疗复发多发性骨髓瘤。
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
Zotero 插件